The Longevity Show with Dr. Hillary Lin
Peptides: What I’m Not Seeing in My Patients | Dr. Mayoni
I’ve heard plenty of big promises about peptides. What I’m seeing in practice is a lot less dramatic, with an important exception: GLP-1s. In this conversation with Dr. Mayoni Gooneratne, we talk about what the evidence can tell us, why the source of an injectable matters, and how GLP-1s fit into conversations about women’s health, nutrition and muscle. We also get into the difference between off-label prescribing, compounded medicines and products sold for research use, and why a promising idea is only one part of the decision. Original conversation hosted by Dr. Mayoni Gooneratne and shared with permission. Learn more about Dr. Mayoni: https://drmhumanhealth.co.uk/dr-mayoni Chapters 00:00 Peptides Beyond GLP-1s 00:25 Off-Label Prescribing & FDA Approval 01:37 Compounding Pharmacies vs. "Research Use" Labs 04:36 Sourcing Safety & Why Batch Testing Matters 06:38 What Can Go Wrong? (ICU Case) 07:34 Beyond Compounds: Lifestyle Medicine First 09:02 Women’s Health, Perimenopause & GLP-1s 11:05 Sustainable Weight Loss & Muscle Preservation 13:48 Final Advice: Beating the Peptide FOMO References : FDA: off-label use — https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label FDA: compounding — https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers FDA: BPC-157 briefing — https://www.fda.gov/media/193343/download This conversation is for education, not personal treatment advice. Discuss medication changes with your clinician.
